Evidence map›Paper›PMID 37342196›Full record

ArticleFrontiers in oncology2023

Identification of a novel MYC target gene set signature for predicting the prognosis of osteosarcoma patients.

Deliang Gong, Qingzhong Zhao, Jun Liu, Shibing Zhao, Chengfeng Yi, Jianwei Lv, Hang Yu, Erbao Bian, Dasheng Tian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Deliang GongDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Qingzhong ZhaoDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Jun LiuDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Shibing ZhaoDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Chengfeng YiDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Jianwei LvDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Hang YuDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Erbao BianDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Dasheng TianDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Second Hospital of Anhui Medical University · CNAnhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is a primary malignant tumor found mainly in teenagers and young adults. Patients have very little long-term survival.

Indexed as

MYC target gene setosteosarcoma (OS)prognosisrisk signatureSTX10

Identifiers

PMID37342196
PMCPMC10277635
OpenAlexW4379473243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.